BioNTech Open to Preferred Partnership as Cancer Drugs Advance

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief executive officer saying he would consider a deal with a partner that gets preferred access to some medicines.

The German biotech’s biggest successes so far came from partnerships, notably the collaboration with Pfizer Inc. for Covid-19 vaccines, CEO Ugur Sahin said in an interview during the JPMorgan Healthcare Conference in San Francisco.